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Abstract
Adapting controlled release technologies to the delivery of DNA has the potential to overcome extracellular barriers that limit
gene therapy. Controlled release systems can enhance gene delivery and increase the extent and duration of transgene expression relative to more traditional delivery methods (e.g., injection). These systems typically deliver vectors locally, which can avoid
distribution to distant tissues, decrease toxicity to nontarget cells, and reduce the immune response to the vector. Delivery vehicles for controlled release are fabricated from natural and synthetic polymers, which function either by releasing the vector into
the local tissue environment or by maintaining the vector at the polymer surface. Vector release or binding is regulated by the effective affinity of the vector for the polymer, which depends upon the strength of molecular interactions. These interactions occur through nonspecific binding based on vector and polymer composition or through the incorporation of complementary binding sites (e.g., biotin–avidin). This review examines the delivery of nonviral and viral vectors from natural and synthetic polymers
and presents opportunities for continuing developments to increase their applicability.
Keywords: gene therapy, tissue engineering, biomaterials, substrate-mediated delivery, plasmid

a sustained release. This review examines the mechanisms of gene delivery from biomaterials and discusses
how continuing advances will increase the applicability
of controlled release to gene delivery.

Introduction
Controlled release systems for low-molecular-weight
drugs and proteins have become a multibillion dollar industry, with products such as Nutropin Depot, Gliadel
wafer, Norplant, and CYPHER Stent. These systems illustrate the potential advantages of controlled release,
which include: (i) drug levels maintained within a desirable range, (ii) localized delivery to a target tissue or cell
type to avoid adverse side effects, (iii) decreased dose or
number of dosages, and (iv) facilitated delivery for fragile compounds (i.e., short half-lives). The adaptation of
controlled release technologies to the delivery of nonviral and viral vectors has the potential to overcome extracellular barriers that limit gene therapy. Controlled release can maintain elevated DNA concentrations in the
cellular microenvironment, which improves gene delivery.1 Localized vector delivery to specific tissues can
avoid distribution to distant tissues, leading to ectopic
gene expression, toxicity to nontarget cells, and a strong
immune response. Additionally, viral and nonviral vectors may have a relatively short half-life,2–4 and delivery
vehicles can prevent their degradation and/or provide

Delivery Mechanisms
Controlled release systems typically employ polymeric
biomaterials that deliver vectors according to two general mechanisms: (i) polymeric release, in which the
DNA is released from the polymer, or (ii) substrate-mediated delivery, in which DNA is retained at the surface.
For polymeric release, DNA is entrapped within the material and released into the environment, with release
typically occurring through a combination of diffusion
and polymer degradation. Polymeric delivery may enhance gene transfer by first protecting DNA from degradation and then maintaining the vector at effective
concentrations, extending the opportunity for internalization. DNA release into the tissue can occur rapidly, as
in bolus delivery, or extend over days to months.5–7 For
rapid release, levels would be expected to rise quickly
and decline as the DNA is cleared or degraded. For sus19
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tained delivery, the concentration may be maintained
within an appropriate range by adjusting the release to
replace DNA that is cleared or degraded. Conversely,
substrate-mediated delivery, also termed solid-phase
delivery, describes the immobilization of DNA to a biomaterial or extracellular matrix, which functions to support cell adhesion as well as migration and places DNA
directly in the cellular microenvironment. The immobilization of DNA to the matrix may seem counterintuitive given the need for cellular internalization to achieve
expression; however, natural and synthetic corollaries
exist for growth factors and viral vectors. Growth factors associate with the extracellular matrix, functioning directly from the matrix or upon release.8 Additionally, many viral vectors associate with the extracellular
matrix as a means to facilitate cellular binding and internalization.9, 10 In substrate-mediated delivery, DNA
is concentrated at the delivery site and targeted to the
cells that are adhered to the substrate.11, 12 Cells cultured
on the substrate can internalize the DNA either directly
from the surface or by degrading the linkage between
the vector and the material.
Molecular interactions between the vector and the
polymer dictate whether the DNA is released from or
bound to the delivery vehicle. Viral and nonviral vectors, which contain negatively charged DNA or RNA
potentially complexed with proteins, cationic polymers,
or cationic lipids, interact with polymeric biomaterials
through nonspecific mechanisms, including hydrophobic, electrostatic, and van der Waals interactions. These
interactions have been well characterized for adsorption and release of proteins from polymeric systems,13, 14
Nonspecific binding depends upon the molecular composition of the vector (e.g., lipid, polymer, protein) and
the relative quantity of each (e.g., N/P). Alternatively,
specific interactions can be introduced through complementary functional groups on the vector and polymer, such as antigen–antibody or biotin–avidin, to control vector binding to the substrate. The effective affinity
of vector for polymer is determined by the strength of
these molecular interactions, which may also be influenced by environmental conditions (e.g., ionic strength,
pH), binding-induced conformational changes, or vector unpacking. Delivery from most polymeric systems
likely occurs through a combination of binding and release mechanisms, and both the vector and the polymer
can be designed to regulate these interactions.
Vehicle Formulations
Vehicles for gene delivery can be fabricated from both
natural and synthetic polymers and processed into a
variety of forms, including nanospheres, microspheres,
or scaffolds. Nanospheres are particles with diameters
ranging from approximately 50 to 700 nm,15 consistent
with the size of viral and nonviral vectors. Nanoparti-
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cles are internalized and release DNA intracellularly.
In contrast, microspheres, with diameters ranging from
2 to 100 μm, are not readily internalized, but retained
within the tissue to release DNA.16, 17 Released DNA
can transfect cells at the delivery site, with the protein
product acting locally or distributed systemically.17, 18
Alternatively, polymeric scaffolds function to define a
three-dimensional space and can either be implanted
or be designed to solidify upon injection. These scaffolds can deliver DNA to cells within the surrounding
tissue or can target those cells infiltrating the scaffold.7,
18 The scaffold can also distribute the vector throughout a three-dimensional space, and transfection on a
three-dimensional construct may extend transgene
expression.19
A variety of natural and synthetic materials have
been employed for DNA delivery, which can be categorized as either hydrophobic [e.g., poly(lactide-co-glycolide) (PLG), polyanhydrides] or hydrophilic polymers
[e.g., hyaluronic acid (HA), collagen, poly(ethylene glycol) (PEG)]. Synthetic polymers such as PLG and polyanhydrides have been widely used in drug delivery applications, as they are biocompatible and available in
a range of copolymer ratios to control their degradation.20 Drug release from these polymers typically occurs through a combination of surface desorption, drug
diffusion, and polymer degradation.21 For DNA delivery, polymer processing techniques are being developed to fabricate a range of geometries and properties
while retaining the activity of the vector during processing and release.22, 23 Alternatively, mild processing conditions can be employed to process hydrophilic polymers into hydrogels. These hydrogels are often more
than 98% water and maintain the activity of encapsulated vectors, which are released by diffusion from the
polymer network.6 Crosslinking the polymer or increasing the density can slow the release and allow network
degradation to control the rate.24–26 These hydrophilic
polymers, along with some hydrophobic polymers, contain functional groups (e.g., carboxylic acids, amines) in
the polymer backbone that can be readily modified, allowing interactions between the polymer and the vector
to be manipulated.
Plasmid delivery
Plasmid DNA delivery by physical methods generally
results in low but sustained expression in vivo, which
is limited by poor uptake due to factors such as degradation and clearance.27, 28 Physical (e.g., ultrasound, hydrodynamic injection) methods are continually being
improved to enhance cellular uptake of DNA by altering cell permeability.27, 29 Plasmid uptake may involve
intrinsic cellular processes, but the processes governing
intracellular transport remain elusive. Following delivery to the nucleus, expression can typically occur over
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time scales of days to weeks or months.29 Extracellular
factors that limit delivery include plasmid clearance or
degradation, which can be mediated by sequence-specific recognition from the immune system. Immune responses to the plasmid are affected by the methylation
pattern of CpG sequences that can affect the duration of
transgene expression.29 Polymeric delivery represents
an alternative approach that can increase residence time
within the tissue and protect against degradation. Plasmids (103–104 bp) have effective hydrodynamic diameters in excess of 100 nm and a highly negative surface
charge density.30 The large size of the DNA limits transport through tissues, resulting in diffusion coefficients
on the order of 10-9 to 10-12 cm2/s,31 and promotes localized delivery when polymers are inserted into a tissue.10
In the following paragraphs, we limit our discussion of
polymeric delivery systems primarily to plasmid delivery, though these systems may also benefit oligonucleotide or siRNA delivery.32
Plasmid DNA interacts weakly with many polymers,
leading to in vitro release from the vehicle with rates
modulated by the polymer properties. Many synthetic
and natural polymers are negatively charged, and thus
the weak interactions likely result from repulsive charge
interactions between plasmid and polymer. Collagenbased materials release plasmid DNA for times ranging
from hours to days.6, 24 HA-based hydrogels also release
the DNA; however, the rate of release can be controlled
by the extent of crosslinking.26, 33 Sustained release and
delayed release was achieved with hydrogels composed
of PEG with lactic acid segments, based on the number
of degradable lactic acid units.25 For hydrogels formed
by crosslinking, the approach must be adjusted to avoid
damaging the integrity of the DNA.25 For synthetic polymers such as PLG, the integrity of the DNA can be affected by degradation of the polymer to lactic acid and
glycolic acid.7 PLG polymers can provide release rates
ranging from a few days to more than 60 days, with the
fabrication method and the polymer composition regulating release.7, 23, 34, 35 Ethylene vinyl-co-acetate (EVAc)
polymers can similarly provide a sustained release of
DNA on the time scale of weeks.36, 37
DNA-releasing polymers administered to multiple
sites in vivo have demonstrated the capacity to transfect cells locally and promote sustained protein production.18 Although successful gene transfer has been
achieved, the design parameters that relate system properties to the quantity and duration of transgene expression are not well understood. For example, an injectable
PLG formulation delivered subcutaneously led to 28 days
of expression with 50 μg of DNA.34 An implantable PLG
scaffold delivering 500 μg of DNA was able to transfect
cells within and adjacent to the scaffold.7 EVAc disks implanted intravaginally induced gene expression for 28
days with 45 μg of DNA.36 Collagen minipellets containing 50 μg of DNA administered intramuscularly elicited
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systemic effects for at least 60 days, which was significantly longer than direct DNA injection.17 Similarly, collagen implanted into a bone defect transfected cells locally with 1 mg of DNA. Controlled studies to correlate
scaffold design with in vivo gene delivery are needed to
optimize the development of delivery systems.
Nanospheres loaded with plasmid DNA represent
an alternative to the traditional complexation agents.
PLG nanoparticles are internalized by cells and a fraction escape the endosome within 10 min of incubation,
which is proposed to occur through charge reversal.38
The DNA likely diffuses from the pores of the nanoparticles, as opposed to decomplexing from a cationic polymer or lipid. Transfection levels achieved in vitro with
these nanoparticles are significantly lower than with a
bolus delivery of lipoplexes.39, 40 However, a substantial increase in expression was observed through 1 week
of culture, suggesting that the nanospheres provided
a controlled release intracellularly. Nanospheres fabricated from natural polymers (gelatin, chitosan) provided transfection that was comparable to that obtained
by Lipofectamine.41 Gelatin was crosslinked to stabilize
the nanospheres and provided some protection against
nuclease degradation.42 Intramuscular delivery of these
nanospheres produced higher and more sustained expression than plasmid DNA.
Although DNA is typically encapsulated and released from materials, cationic groups can be attached
to the material to promote DNA binding. Collagen was
cationized through modification with amino groups or
polylysine43 and degradation of the collagen led to release of the bound DNA. Alternatively, PEI (polyethylenimine) or polylysine was bound to or blended with
the material,44, 45 resulting in DNA binding and some
cellular transfection in vitro. Similarly, plasmid DNA
adsorbed onto PLG microparticles coated with the cationic surfactant cetyltrimethylammonium bromide was
able to transfect dendritic cells in vitro.46 Binding of plasmid DNA to a cationic material may exhibit limited cellular internalization due to the strong interactions between the DNA and the material. The alternative is to
allow the DNA to form complexes in solution and then
immobilize the complexes to the polymers.

DNA Complex Delivery
Although plasmid DNA provides transfection in vivo,
packaging DNA with cationic lipids or polymers can facilitate uptake and transfection in vitro and in vivo.27, 29, 47
Cationic polymers and lipids protect DNA against degradation by nucleases and serum components, create a
less negative surface charge, and can be designed to target delivery to specific cell types through receptor–ligand interactions.47 These complexation agents can also
facilitate intracellular trafficking, which includes endo-
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somal escape, cytoplasmic transport, and nuclear entry,
while also dissociating from the DNA to allow expression.27, 48
Polymeric release of DNA complexes may enhance or
localize gene transfer in vivo and in vitro; however, interactions between the vector and the polymer can impact
incorporation and release. The presence of complexation
agents can maintain the stability of DNA complexes during polymer processing 49, 50 and in some cases increase
encapsulation efficiency.32 Porous PLG or collagen scaffolds with encapsulated polyplexes or lipoplexes achieved
substantial transfection in vitro 6, 45, 51 and in vivo,6 but with
significantly altered release profiles compared to plasmid
DNA. The complexation reagents interact with the biomaterial or with adsorbed serum components, which are
known to interact with DNA complexes.52, 53 PEI/DNA
complexes and lipoplexes were slowly released from collagen, and addition of a protective copolymer to the complexes increased release, presumably by decreasing interactions between collagen and the complex.6 While low
N/P ratios supported release from synthetic polymers,50
high N/P ratios significantly limited release.32, 51 Interestingly, these vector–polymer interactions resulted in released complexes with a lower N/P ratio than the encapsulated complexes.54
Interactions between complexation agents and the
polymer have been adapted to immobilize DNA complexes specifically to a substrate. Poly(L-lysine) (PLL) and
PEI were modified with biotin residues for subsequent
complexation with DNA and binding to a neutravidin
substrate.12, 55 Complexes were formed with mixtures of
biotinylated and nonbiotinylated cationic polymer at a
constant N/P ratio. Release studies demonstrated that
only 25% of immobilized DNA complexes were released
over an 8-day period, with approximately 15% released
within the first 24 h. For complexes formed with PLL, the
number of biotin groups and their distribution among the
cationic polymers were critical determinants of both binding and transfection. The number of biotin groups in the
complex was manipulated through the fraction of biotinylated PLL used for complex formation and the number
of biotin residues per PLL. Increasing the number of biotin groups per complex led to increased binding.12 However, in vitro transfection was maximal when complexes
contained biotin residues attached to a small fraction of
the cationic polymers.55 At this condition, less than 100
ng of immobilized DNA mediated transfection, which
was increased 100-fold relative to bolus delivery of similar complexes.12 Additionally, transfection was observed
only in the location to which complexes were bound, suggesting the possibility of spatially regulating DNA delivery. For complexes formed with PEI, substantial transfection was observed in vitro but was independent of the
number of biotin groups present on the complex, suggesting that complex immobilization occurred through nonspecific interactions.55
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Nonspecific binding of DNA complexes to substrates
has been employed with other systems to mediate delivery. PLGA and collagen membranes were coated with
phosphatidyl glycerol (1–5%) to support binding of
complexes formed with polyamidoamine dendrimers.56
Vectors were slowly released from this scaffold, yielding transfection in vitro comparable to bolus transfection
controls. In vivo studies demonstrated a six- to eightfold
enhancement in transfection relative to plasmid DNA
delivery. Adsorption of PEI/DNA complexes to silica
nanoparticles 57, 58 resulted in transgene expression in vitro comparable to that observed by bolus delivery and
with reduced toxicity. Plasmid DNA has also been incorporated into inorganic calcium phosphate coprecipitates that are adsorbed onto PLGA matrices, which are
mostly released by 48 h.59
Virus Delivery
Viral vectors are more widely used than nonviral vectors due to their increased efficiency, yet their use requires further developments to make them less toxic
and immunogenic.60 Retroviruses and adenoviruses are
the most widely used vectors in clinical trials, although
other viruses are being used (herpes simplex, adeno-associated). Retroviruses offer the potential for long-term
gene expression through integration into the host cell
genome; however, obtaining efficient delivery, transducing nondividing cells, and achieving stable expression at an appropriate level are challenges that persist.
Adenoviral vectors, on the other hand, can transduce a
wide range of cells, including nondividing ones, and are
relatively safe, though they can elicit a strong immune
response. The stability of gene expression by adenoviral vectors may also be insufficient. Viruses can be engineered to be replication deficient, to reduce the immune response, and to target the virus to an appropriate
cell type. Polymeric delivery may enhance delivery efficiency of viral vectors by overcoming some of the extracellular barriers.
Viral particles are composed of a nucleic acid genome surrounded by a capsid of proteins, which have
the potential to interact with a polymeric delivery system. Most studies examining polymeric virus delivery
have employed adenoviral vectors, which may provide
a foundation for the use of other viral vector systems.
Interactions with the material could provide some stability against degradation, as viruses can have half-lives
on the order of hours at 37°C. This interaction between
the virus and the polymer may also affect the immune
response, which can target the vector or the transduced
cells, thus decreasing transduction or the activity of the
secreted protein.61–63 Polymeric delivery of viral vectors
may reduce recognition by the immune system by limiting binding of neutralizing antibodies and minimizing
the amount of DNA necessary for gene transfer.64, 65 En-
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capsulated adenoviral vectors provided gene transfer in
preimmunized mice,65, 66 with encapsulated vectors inducing 45-fold lower anti-adenovirus titers than those
obtained with direct injection.65, 67
Viruses can be encapsulated and released from both
synthetic and natural materials, with the preparation
procedure affecting both the fraction released and the
activity. Incorporation of adenovirus into collagen resulted in release of 10 to 20% depending upon the collagen content.5, 68, 69 In vivo application of collagen loaded
with viral particles resulted in localized delivery and extended availability at the site of implantation. The viral particles retained their activity in vitro and in vivo,
with expression at implantation sites in vivo lasting for
months without redosing.5, 64, 65, 67, 68, 70 Alternatively,
collagen/alginate microspheres released 100% of the encapsulated virus within 48 h and were able to transduce
cells in vivo at levels comparable to equivalent amounts
of injected adenovirus.71 Microspheres composed of
PLG released 14 to 45% of encapsulated virus in vitro,
depending on fabrication procedures.64, 65 Virus was released for more than a week, with 70 to 90% released
within the first 4 days 64, 65; however, most of the viable
virus was released during the first 2 days.65
Substrate-mediated delivery of viral vectors has been
achieved through both specific and nonspecific binding of the virus to the polymer. Polystyrene beads and
microspheres bind adenovirus vectors nonspecifically,

which increased transduction efficiency relative to free
vector delivery and targeted gene expression in cells in
contact with sphere in vitro and in vivo.72, 73 Specific interactions of viral particles with the polymer have been
incorporated through modification of the biomaterial or
the virus with functional groups, such as antibodies or
biotin residues. Collagen gels modified with antibodies
to immobilize vectors localized transduction in vivo relative to control conditions.11, 74, 75 Alternatively, adenovirus vectors have been chemically modified with biotin
groups that are then bound to avidin-conjugated microspheres.76 This approach transduced cells immediately
adjacent to the beads in vitro and enhanced transgene
expression for cells that are not readily transduced with
adenovirus.76 Recently, viruses have been engineered
with functional groups in the viral shell, which would
enable binding without chemical modification that can
inactivate the virus.77–79
Applications
Polymeric delivery of nonviral and viral vectors generally promotes gene transfer to cells within or adjacent to
the implant. Depending on the choice of gene product,
the protein produced by transfected cells may function
either locally or systemically. Localized protein production is being used to stimulate an immune response, deliver a suicide gene, or promote wound healing. Alterna-

Table 1. In vivo studies involving therapeutically relevant genes delivered with polymeric systems.
Vector

Material

Species/location

Gene

Plasmid
Collagen
Rat/femur
BMP-4/hPTH1-34
Plasmid
Collagen
Canine/bone
hPTH1-34
Plasmid
Collagen
Mice/intramuscular
FGF-4
Plasmid
PLG
Rat/subdermal
PDGF
				
Adenovirus
PVA/
Rat/subdermal
PDGF
(FGF-2 target)
collagen
Canarypox virus
Gelatin
Mouse/intratumoral
IL-2, IL-12, TNF-a
Plasmid
Collagen
Rabbit/ear
PDGF
				
Poly-d-lysine/
Collagen
Rat/optic nerve
FGF2, BDNF, NT-3
plasmid
Adenovirus
Collagen
Rabbit/ear
PDGF, FGF-2, VEGF
				
Adenovirus/
Collagen
Rat/intramuscular
PDGF, FGF-2, FGF-6
plasmid
Plasmid
PLG
Mouse/subdermal
Endothelial locus-1
Plasmid
Gelatin
Mouse/renal subcapsule
MMP-1
Plasmid
Chitosan
Mouse/intranasal
RSV antigens
				
Plasmid
EVAc
Mouse/intravaginal
LDH-C4
Plasmid
Gelatin
Rabbit/hindlimb
FGF-4
Adenovirus
Collagen
Mouse/dermal wound
PDGF-B
				
Adenovirus
Collagen
Rabbit/dermal wound
PDGF-B

Result

Ref

Bone formation
Bone formation over 1-cm gap
Platelets increased for 60 days
Enhanced matrix deposition
and vascularization
Granulation tissue

[88]
[18]
[17]

Growth inhibition of tumors
Granulation tissue and
epithelialization
Survival of axotomized RGCs

[86]
[92]
[91]

Granulation tissue deposition,
wound closure, vascularization
Early angiogenesis, muscle repair

[68]
[93]

Small blood vessel formation
Decreased blood urea nitrogen
Reduction of viral titers and viral
antigen load
Induction of specific IgA
Angiogenesis
Granulation tissue and
vascularization
Granulation tissue, no toxicity

[7]
[69]

[34]
[43]
[85]
[36]
[101]
[70]
[70]

24

tively, protein secreted by locally transfected cells can be
distributed systemically, which has applications to disorders such as hemophilia. The versatility of polymeric
delivery to alter protein concentrations locally or systemically may impact numerous applications in vivo and
in vitro. Table 1 lists studies that have employed polymeric delivery in vivo to induce physiological responses.
Gene Therapy
Numerous clinical trials have been completed or are
pending for a multitude of pathologies, including cancer
(e.g., colorectal, bladder, and brain), monogenic disease,
and vascular disease. Most trials have not shown significant therapeutic efficacy or clinically useful responses,
likely due to inefficient delivery, lack of stable gene expression, and immune clearance of either the vector or
the cells expressing a foreign gene.80–84 Polymeric-based
gene delivery systems may enhance delivery of the vector and extend the duration of transgene expression to
achieve sufficient protein quantities that act locally or
systemically. For example, intranasally delivered nanospheres loaded with plasmid encoding RSV antigens reduced viral titers and viral antigen load after acute RSV
infection in mice.85 Additionally, IL-2, IL-12, and TNF-α
expression induced by a virus-releasing gelatin sponge
inhibited tumor growth in heterotopic nodules of tumor-bearing mice.86
Tissue Engineering
The challenge of tissue engineering lies in creating an environment that provides the appropriate combination of
signals to induce proper cell function and restore normal
tissue function. The scaffold functions as a support for
cell growth and localized DNA delivery can provide the
signals to direct progenitor cell differentiation. Although
several fundamental requirements for the scaffold structure have been identified,87 the design principles underlying gene delivery in tissue regeneration remain to be
identified. Currently, a phase I clinical study using collagen-embedded adenovirus encoding PDGF has begun
to evaluate the safety and maximum tolerated dose for
treatment of diabetic ulcers.70 Collagen-based delivery of
nonviral or viral DNA has been employed in models of
bone,18, 88, 89 cartilage,90 and nerve regeneration 91; wound
healing 68–70, 92; muscle repair 93; and cardiovascular disease.94 Alternatively, viruses have been tethered to endovascular microcoils,74 stents,75 and heart valve replacement cusps 95 to localize delivery to the arterial wall and
avoid spread to distal sites.75 Porous PLG scaffolds releasing plasmid DNA were able to transfect cells within
and around the scaffold, with sufficient expression of
PDGF to promote tissue formation.7 While these studies
have illustrated the potential for extending the production of growth factors locally, adapting the delivery strategies to control transgene expression spatially (microme-
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ters to millimeters) or temporally (days to months) may
re-create the environmental complexity present during
tissue formation.96 The ability to regulate expression of
one or more factors in time and space may be critical to
the engineering of complex tissue architectures, such as
those found in vascular networks and the nervous system. These systems would also increase our understanding of the biology behind tissue formation, which would
serve to identify how gene delivery can best augment the
regenerative process.
Functional Genomics
Transfected cell arrays represent a high-throughput approach to correlate gene expression with functional cell
responses, based on gene delivery from a surface.97 In
principle, this system can be employed for numerous
studies, such as screening large collections of cDNAs
97 or targets for therapeutic intervention.98 Transfected
cell arrays were formed using a substrate-mediated approach in which plasmids or adenoviruses were mixed
with collagen and spotted onto glass slides or into
wells.97–99 Plated cells were transfected and could be analyzed for cellular responses using a variety of imaging
or biochemical techniques. Further development of the
substrate-mediated approach requires the development
of a cost-effective delivery system that efficiently transfects a wide variety of primary cells and cell lines, while
allowing for spatially controlled DNA within the different domains.97, 100
Conclusions
In comparison to traditional gene delivery systems, controlled release can enhance gene delivery by increasing
the extent and duration of transgene expression, while reducing the need for multiple interventions. Additionally,
localized vector delivery to specific tissues can avoid distribution to distant tissues, decrease toxicity to nontarget
cells, and reduce the immune response. These polymerbased gene delivery systems capitalize on both specific
and nonspecific interactions between the biomaterial and
the vector, to achieve either release into the extracellular
space or immobilization at the surface. While the potential to use these polymeric systems has been established,
the design parameters by which to optimize or control
gene transfer are not well understood. Vector and biomaterial development, combined with studies that correlate
system properties (e.g., dose, release rate) with the quantity and duration of protein production and the number
and location of cells expressing the transgene, will lead
to molecular-scale design of delivery systems. The development of these systems may increase the efficacy within
current gene therapy trials and may also extend the applicability of gene delivery to other areas such as tissue
engineering and functional genomics.
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